J. Prakash, S. S. Niwas, A. Parekh, L. K. Pandey, L. Sharatchandra et al., Acute kidney injury in late pregnancy in developing countries, Ren Fail, vol.32, pp.309-313, 2010.

F. Mattar, B. M. Sibai, . Eclampsia, and . Viii, Risk factors for maternal morbidity, Am J Obstet Gynecol, vol.182, pp.307-312, 2000.

A. Youssef, F. Righetti, D. Morano, N. Rizzo, and A. Farina, Uterine artery Doppler and biochemical markers (PAPP-A, PIGF, sFlt-1, Pselectin, NGAL) at 11 1 0 to 13 1 6 weeks in the prediction of late (. 34 weeks) pre-eclampsia, Prenat Diagn, vol.31, pp.1141-1146, 2011.

P. Stratta, L. Besso, C. Canavese, A. Grill, T. Todros et al., Is pregnancy-related acute renal failure a disappearing clinical entity?, Ren Fail, vol.18, pp.575-584, 1996.

J. Prakash, H. Kumar, D. K. Sinha, P. G. Kedalaya, L. K. Pandey et al., Acute renal failure in pregnancy in a developing country: Twenty years of experience, Ren Fail, vol.28, pp.309-313, 2006.

J. Prakash, R. Vohra, I. A. Wani, A. S. Murthy, P. K. Srivastva et al., Decreasing incidence of renal cortical necrosis in patients with acute renal failure in developing countries: A single-centre experience of 22 years from Eastern India, Nephrol Dial Transplant, vol.22, pp.1213-1217, 2007.

J. Prakash, K. Tripathi, L. K. Pandey, S. Sahai, U. Srivastava et al., Spectrum of renal cortical necrosis in acute renal failure in eastern India, Postgrad Med J, vol.71, pp.208-210, 1995.

J. P. Grü-nfeld, D. Ganeval, and F. Bournérias, Acute renal failure in pregnancy, Kidney Int, vol.18, pp.179-191, 1980.

K. S. Chugh, P. C. Singhal, B. K. Sharma, Y. Pal, M. T. Mathew et al., Acute renal failure of obstetric origin, Obstet Gynecol, vol.48, pp.642-646, 1976.

N. Arora, K. Mahajan, J. N. Taraphder, and A. , Pregnancy-related acute renal failure in eastern India, Int J Gynaecol Obstet, vol.111, pp.213-216, 2010.

B. Sibai, G. Dekker, and M. Kupferminc, Pre-eclampsia, Lancet, vol.365, pp.785-799, 2005.

D. K. Packham, D. C. Mathews, K. F. Fairley, J. A. Whitworth, and P. S. Kincaidsmith, Morphometric analysis of pre-eclampsia in women biopsied in pregnancy and post-partum, Kidney Int, vol.34, pp.704-711, 1988.

A. J. Drakeley, L. Roux, P. A. , A. J. Penny, and J. , Acute renal failure complicating severe preeclampsia requiring admission to an obstetric intensive care unit, Am J Obstet Gynecol, vol.186, pp.253-256, 2002.

S. Venkatesha, M. Toporsian, C. Lam, J. Hanai, T. Mammoto et al., Nat Med, vol.12, pp.642-649, 2006.

R. J. Levine, C. Lam, C. Qian, K. F. Yu, S. E. Maynard et al., CPEP Study Group: Soluble endoglin and other circulating antiangiogenic factors in preeclampsia, N Engl J Med, vol.355, pp.992-1005, 2006.

S. Salahuddin, Y. Lee, M. Vadnais, B. P. Sachs, S. A. Karumanchi et al., Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy, Am J Obstet Gynecol, vol.197, pp.28-29, 2007.

H. P. Gerber, F. Condorelli, J. Park, and N. Ferrara, Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia, J Biol Chem, vol.272, pp.23659-23667, 1997.

R. Tal, A. Shaish, I. Barshack, S. Polak-charcon, A. Afek et al., Effects of hypoxia-inducible factor1alpha overexpression in pregnant mice: Possible implications for preeclampsia and intrauterine growth restriction, Am J Pathol, vol.177, pp.2950-2962, 2010.

G. Girardi, D. Yarilin, J. M. Thurman, V. M. Holers, and J. E. Salmon, Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction, J Exp Med, vol.203, pp.2165-2175, 2006.

J. Hanna, D. Goldman-wohl, Y. Hamani, A. I. Greenfield, C. Natanson-yaron et al., Decidual NK cells regulate key developmental processes at the human fetal-maternal interface, Nat Med, vol.12, pp.1065-1074, 2006.

G. Wallukat, V. Homuth, T. Fischer, C. Lindschau, B. Horstkamp et al., Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor, J Clin Invest, vol.103, pp.945-952, 1999.

M. T. Raijmakers, R. Dechend, and L. Poston, Oxidative stress and preeclampsia: Rationale for antioxidant clinical trials, Hypertension, vol.44, pp.374-380, 2004.

M. Noris and G. Remuzzi, Thrombotic microangiopathy after kidney transplantation, Am J Transplant, vol.10, pp.1517-1523, 2010.

F. Fakhouri, L. Roumenina, F. Provot, M. Sallée, S. Caillard et al., Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations, J Am Soc Nephrol, vol.21, pp.859-867, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00512540

F. Fakhouri and V. Frémeaux-bacchi, Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura?, Nat Clin Pract Nephrol, vol.3, pp.679-687, 2007.

J. A. Hovinga, S. K. Vesely, D. R. Terrell, B. Lammle, and J. N. George, Survival and relapse in patients with thrombotic thrombocytopenic purpura, Blood, vol.115, pp.1500-1511, 2010.

B. Koehl, O. Boyer, N. Biebuyck-gougé, M. Kossorotoff, V. Frémeaux-bacchi et al., Neurological involvement in a child with atypical hemolytic uremic syndrome, Pediatr Nephrol, vol.25, pp.2539-2542, 2010.

A. L. Lapeyraque, M. Malina, V. Fremeaux-bacchi, T. Boppel, M. Kirschfink et al., Eculizumab in severe Shiga-toxinassociated HUS, N Engl J Med, vol.364, pp.2561-2563, 2011.

C. Frank, D. Werber, J. P. Cramer, M. Askar, M. Faber et al., HUS Investigation Team: Epidemic profile of Shiga-toxin-producing Escherichia coli O104: H4 outbreak in Germany, N Engl J Med, vol.365, pp.1771-1780, 2011.

M. Furlan, R. Robles, M. Galbusera, G. Remuzzi, P. A. Kyrle et al., Lämmle B: von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome, N Engl J Med, vol.339, pp.1578-1584, 1998.

M. Noris and G. Remuzzi, Atypical hemolytic-uremic syndrome, N Engl J Med, vol.361, pp.1676-1687, 2009.
URL : https://hal.archives-ouvertes.fr/hal-01793663

L. Quintrec, M. Roumenina, L. Noris, M. Frémeaux-bacchi, and V. , Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes, Semin Thromb Hemost, vol.36, pp.641-652, 2010.

M. A. Dragon-durey, S. K. Sethi, A. Bagga, C. Blanc, J. Blouin et al., Frémeaux-Bacchi V: Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome, J Am Soc Nephrol, vol.21, pp.2180-2187, 2010.

F. Fakhouri, M. Jablonski, J. Lepercq, J. Blouin, A. Benachi et al., Frémeaux-Bacchi V: Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome, Blood, vol.112, pp.4542-4545, 2008.

L. Quintrec, M. Lionet, A. Kamar, N. Karras, A. Barbier et al., Frémeaux-Bacchi V: Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation, Am J Transplant, vol.8, pp.1694-1701, 2008.

M. Morigi, M. Galbusera, S. Gastoldi, M. Locatelli, S. Buelli et al., Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis, J Immunol, vol.187, pp.172-180, 2011.

V. Eremina, J. A. Jefferson, J. Kowalewska, H. Hochster, M. Haas et al.,

H. P. Gerber, N. Ferrara, L. Barisoni, and C. E. Alpers, Quaggin SE: VEGF inhibition and renal thrombotic microangiopathy, N Engl J Med, vol.358, pp.1129-1136, 2008.

F. Fakhouri, J. P. Vernant, A. Veyradier, M. Wolf, G. Kaplanski et al., Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases, Blood, vol.106, pp.1932-1937, 2005.

M. Scully, V. Mcdonald, J. Cavenagh, B. J. Hunt, I. Longair et al., A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura, Blood, vol.118, pp.1746-1753, 2011.

A. Veyradier, B. Obert, A. Houllier, D. Meyer, and J. P. Girma, Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases, Blood, vol.98, pp.1765-1772, 2001.

M. Noris, J. Caprioli, E. Bresin, C. Mossali, G. Pianetti et al., Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype, Clin J Am Soc Nephrol, vol.5, pp.1844-1859, 2010.

S. K. Vesely, J. N. George, B. Lämmle, J. D. Studt, L. Alberio et al., ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Relation to presenting features and clinical outcomes in a prospective cohort of 142 patients, Blood, vol.102, pp.60-68, 2003.

P. M. Mannucci, M. T. Canciani, I. Forza, F. Lussana, A. Lattuada et al., Changes in health and disease of the metalloprotease that cleaves von Willebrand factor, Blood, vol.98, pp.2730-2735, 2001.

B. Gall, Y. A. Berry, B. Birchman, D. Hayashi, A. Dansereau et al., Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura, J Obstet Gynaecol Can, vol.32, pp.1167-1171, 2010.

E. F. Chakravarty, E. R. Murray, A. Kelman, and P. Farmer, Pregnancy outcomes after maternal exposure to rituximab, Blood, vol.117, pp.1499-1506, 2011.

E. Ton, J. Tekstra, P. M. Hellmann, I. H. Nuver-zwart, and J. W. Bijlsma, Safety of rituximab therapy during twins' pregnancy. Rheumatology, vol.50, pp.806-808, 2011.

S. K. Vesely, X. Li, J. R. Mcminn, D. R. Terrell, and J. N. George, Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, Transfusion, vol.44, pp.1149-1158, 2004.

Y. Ezra, M. Rose, and A. Eldor, Therapy and prevention of thrombotic thrombocytopenic purpura during pregnancy: A clinical study of 16 pregnancies, Am J Hematol, vol.51, pp.1-6, 1996.

R. Raman, S. Yang, H. M. Wu, and S. R. Cataland, ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancy, Br J Haematol, vol.153, pp.277-279, 2011.

M. Scully, R. Starke, R. Lee, I. Mackie, S. Machin et al., Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura, Blood Coagul Fibrinolysis, vol.17, pp.459-463, 2006.

M. Kaplan, Eculizumab (Alexion), Curr Opin Investig Drugs, vol.3, pp.1017-1023, 2002.

T. M. Woodruff, K. S. Nandakumar, and F. Tedesco, Inhibiting the C5-C5a receptor axis, Mol Immunol, vol.48, pp.1631-1642, 2011.

K. Mckeage, Eculizumab: A review of its use in paroxysmal nocturnal haemoglobinuria, Drugs, vol.71, pp.2327-2345, 2011.

V. Chatelet, V. Frémeaux-bacchi, T. Lobbedez, M. Ficheux, H. De-ligny et al., Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome, Am J Transplant, vol.9, pp.2644-2645, 2009.

J. C. Davin, V. Gracchi, A. Bouts, J. Groothoff, L. Strain et al., Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation, Am J Kidney Dis, vol.55, pp.708-711, 2010.

R. A. Gruppo and R. P. Rother, Eculizumab for congenital atypical hemolytic-uremic syndrome, N Engl J Med, vol.360, pp.544-546, 2009.

C. F. Larrea, F. Cofan, F. Oppenheimer, J. M. Campistol, G. Escolar et al., Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation, Transplantation, vol.89, pp.903-904, 2010.

C. J. Mache, B. Acham-roschitz, V. Frémeaux-bacchi, M. Kirschfink, P. F. Zipfel et al., Complement inhibitor eculizumab in atypical hemolytic uremic syndrome, Clin J Am Soc Nephrol, vol.4, pp.1312-1316, 2009.

J. Nü-rnberger, T. Philipp, O. Witzke, O. Saez, A. Vester et al., Eculizumab for atypical hemolytic-uremic syndrome, N Engl J Med, vol.360, pp.542-544, 2009.

A. V. Danilov, H. Smith, S. Craigo, D. M. Feeney, V. Relias et al., Paroxysmal nocturnal hemoglobinuria (PNH) and pregnancy in the era of eculizumab, Leuk Res, vol.33, pp.4-5, 2009.

R. Marasca, V. Coluccio, R. Santachiara, G. Leonardi, G. Torelli et al., Pregnancy in PNH: Another eculizumab baby, Br J Haematol, vol.150, pp.707-708, 2010.

R. Kelly, L. Arnold, S. Richards, A. Hill, C. Bomken et al., The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab, Br J Haematol, vol.149, pp.446-450, 2010.

A. Gul, H. Aslan, A. Cebeci, I. Polat, S. Ulusoy et al., Maternal and fetal outcomes in HELLP syndrome complicated with acute renal failure, Ren Fail, vol.26, pp.557-562, 2004.

B. Haddad, J. R. Barton, J. C. Livingston, R. Chahine, and B. M. Sibai, HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome versus severe preeclampsia: Onset at , or 528.0 weeks' gestation, Am J Obstet Gynecol, vol.183, pp.1475-1479, 2000.

K. A. Abraham, G. Connolly, J. Farrell, and J. J. Walshe, The HELLP syndrome, a prospective study, Ren Fail, vol.23, pp.705-713, 2001.

B. M. Sibai, M. K. Ramadan, I. Usta, M. Salama, B. M. Mercer et al., Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome), Am J Obstet Gynecol, vol.169, pp.1000-1006, 1993.

N. Y. Selçuk, A. R. Odabas, R. Cetinkaya, and H. Z. Tonbul, Outcome of pregnancies with HELLP syndrome complicated by acute renal failure (1989-1999), Ren Fail, vol.22, pp.319-327, 2000.

K. A. Abraham, M. Kennelly, A. M. Dorman, and J. J. Walshe, Pathogenesis of acute renal failure associated with the HELLP syndrome: A case report and review of the literature, Eur J Obstet Gynecol Reprod Biol, vol.108, pp.99-102, 2003.

J. R. Barton, C. A. Riely, T. A. Adamec, D. R. Shanklin, A. D. Khoury et al., Hepatic histopathologic condition does not correlate with laboratory abnormalities in HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count), Am J Obstet Gynecol, vol.167, pp.1538-1543, 1992.

L. Katz, M. M. De-amorim, J. N. Figueiroa, and J. L. Pinto-e-silva, Postpartum dexamethasone for women with hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome: A double-blind, placebo-controlled, randomized clinical trial, Am J Obstet Gynecol, vol.198, pp.283-284, 2008.

S. D. Eckford, J. L. Macnab, M. L. Turner, D. Plews, and W. A. Liston, Plasmapheresis in the management of HELLP syndrome, J Obstet Gynaecol, vol.18, pp.377-379, 1998.

J. E. Salmon, C. Heuser, M. Triebwasser, M. K. Liszewski, D. Kavanagh et al., Mutations in complement regulatory proteins predispose to preeclampsia: A genetic analysis of the PROMISSE cohort, PLoS Med, vol.8, p.1001013, 2011.

X. Qing, P. B. Redecha, M. A. Burmeister, S. Tomlinson, D. 'agati et al., Targeted inhibition of complement activation prevents features of preeclampsia in mice, Kidney Int, vol.79, pp.331-339, 2011.

P. Redecha, R. Tilley, M. Tencati, J. E. Salmon, D. Kirchhofer et al., Tissue factor: A link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury, Blood, vol.110, pp.2423-2431, 2007.

J. M. Shamonki, J. E. Salmon, E. Hyjek, and R. N. Baergen, Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies, Am J Obstet Gynecol, vol.196, pp.167-168, 2007.